Baloxavir marboxil use for critical human infection of avian influenza A H5N6 virus

Wenda Guan, Rong Qu, Lihan Shen, Kailin Mai, Weiqi Pan, Zhengshi Lin, Liping Chen, Ji Dong, Jiawei Zhang, Pei Feng, Yunceng Weng, Minfei Yu, Peikun Guan, Jinchao Zhou, Chuanmeizi Tu, Xiao Y. Wu, Yang Wang, Chunguang Yang, Yun Ling, Sheng Le, Yangqing Zhan, Yimin Li, Xiaoqing Liu, Heyan Zou, Ziqi Huang, Hongxia Zhou, Qiubao Wu, Wenjie Zhang, Jiayang He, Teng Xu, Nanshan Zhong, Zifeng YangmedRxiv 2023 · DOI

Abstract

Highly pathogenic avian influenza A (H5N6) virus continues to pose a significant public health threat due to its high mortality rate and increasing frequency of human infection. This study analyzes the clinical progression and treatment outcomes of five patients with critical H5N6 infections. While standard oseltamivir treatment often proved insufficient against high viral loads, the introduction of baloxavir marboxil—a cap-dependent endonuclease inhibitor—resulted in a rapid and significant reduction in respiratory viral levels. Despite this antiviral potency, clinical outcomes were ultimately determined by the severity of pre-existing conditions and the progression of multi-organ dysfunction. The study identifies specific cytokine signatures in sputum and serum that serve as indicators for ARDS and sepsis progression, respectively.

Introduction

Avian influenza A (H5N6) is characterized by severe clinical manifestations and a case fatality rate approaching 40%. Standard therapeutic interventions typically rely on neuraminidase inhibitors (NAIs) like oseltamivir. However, the efficacy of NAIs is often compromised by delayed administration or exceptionally high viral replication rates. This research investigates the clinical utility of baloxavir marboxil in a cohort of five critically ill patients, providing a longitudinal analysis of viral dynamics, cytokine responses, and organ failure.

Methods

The researchers conducted a retrospective longitudinal study of five laboratory-confirmed H5N6 patients in Guangdong, China (2021–2022). All patients initially received oseltamivir but were transitioned to or supplemented with baloxavir marboxil when respiratory viral loads remained elevated (>5 log10 copies/mL).

Clinical monitoring included daily Sequential Organ Failure Assessment (SOFA) scores to track systemic organ dysfunction. Viral loads were quantified across multiple sites—including sputum, throat swabs, blood, and urine—using RT-PCR and metagenomic next-generation sequencing (mNGS). Additionally, a 48-plex cytokine panel was employed to analyze protein concentrations in both sputum and serum, aiming to correlate immunological signatures with clinical deterioration.

Viral Dynamics and Antiviral Efficacy

A primary finding of the study is the superior potency of baloxavir marboxil in reducing viral load compared to oseltamivir. Baloxavir targets the virus’s ability to replicate at an earlier stage of the life cycle. In this cohort, the administration of baloxavir led to an average 200-fold reduction in sputum viral load.

Crucially, the study highlights a discrepancy between sampling sites. Throat swabs frequently showed low or undetectable viral loads while sputum samples remained significantly high. This suggests that relying solely on upper respiratory swabs may lead to a premature and false conclusion of viral clearance in severe cases, emphasizing the need for lower respiratory tract monitoring.

Immunological Signatures of Progression

The research identified distinct "indicator cytokines" that reflected the severity of lung injury and systemic infection:

  • ARDS Progression (Sputum): Levels of IL-18, IL-6, HGF, and M-CSF in the sputum were identified as key indicators of pulmonary deterioration.
  • Sepsis Progression (Serum): A broader array of 18 cytokines—including IL-1α, IL-1β, IL-1RA, IFN-γ, and IL-6—correlated with increasing SOFA scores and systemic organ failure.

While baloxavir effectively reduced the viral load and some proinflammatory cytokines in the sputum, its impact on systemic (serum) cytokine levels was more limited. This suggests that once a "cytokine storm" is established and multi-organ failure begins, antiviral intervention alone may not be sufficient to reverse the inflammatory cascade.

Determinants of Clinical Outcome

Despite the rapid viral suppression achieved by baloxavir, three of the five patients died. The study found that survival was not dictated by viral load alone but by three primary factors:

  1. Pre-existing Conditions: Nonsurvivors had more severe comorbidities, such as hypertension and diabetes.
  2. Organ Dysfunction: A steady increase in SOFA scores, particularly involving the cardiovascular and renal systems, was a hallmark of mortality.
  3. Immune Response: Survivors exhibited a more robust and timely H5N6-specific antibody response compared to nonsurvivors.

Conclusion

Baloxavir marboxil is a highly effective antiviral for reducing the viral burden in human H5N6 infections, even when initiated late in the disease course. However, the study underscores that in critical cases, the window for effective antiviral-only intervention may be narrow. The persistence of systemic inflammation and multi-organ failure despite viral clearance suggests that future treatment protocols should explore the combination of potent antivirals like baloxavir with immunomodulatory therapies to address the lethal host inflammatory response.

Summary updated

Abstract

Abstract Background Recent increase in human infections of highly pathogenic avian influenza H5N6 virus and its high mortality have raised concerns. Methods To analyze evolution of outcomes, longitudinal clinical data and specimens were collected from five patients infected with H5N6 virus after admission. All patients received antiviral treatment either sequentially or in combination of oseltamivir with baloxavir. Severity of illness, and viral load in sputum, urine and blood, and cytokine levels in serum and sputum were serially analyzed. Results When delayed oseltamivir showed poor effects on high respiratory viral load, baloxavir was prescribed and viral load had a rapid reduction. All patients developed acute respiratory distress syndrome (ARDS) and sepsis within one week after disease onset, three patients died eventually. Nonsurvivors had more severe preexisting condition, extrapulmonary organ dysfunction and insufficient H5N6 virus-specific antibody response. Grouped by delta SOFA on the sample collection date, serum levels of IL-1α, IL-1β, IL-1RA, MIF, Mig, MIP-1α, IFN-γ, IL-12p40, IL-16, IL-18, IL-2Rα, IL-6, basic FGF, G-CSF, HGF, M-CSF, SCF were identified as indicator cytokines reflecting sepsis progression; and sputum levels of IL-18, IL-6, HGF, M-CSF were indicators of ARDS progression. Comparisons of cytokine levels before, during and after baloxavir treatment suggested that, baloxavir may also reduce a few indicator cytokines in sputum and serum that related to viral load and multi-organ dysfunction. Conclusions Baloxavir can effectively reduce viral load and few proinflammatory cytokines associated with deterioration. However, disease outcome is determined by severity of preexisting conditions and multi-organ dysfunction. Highlights (1) Baloxavir potently decreased viral load in avian influenza H5N6 human infections. (2) Preexisting conditions, extrapulmonary dysfunction and systemic inflammation determined prognosis of H5N6 patients. (3) Indicator cytokines in sputum and serum reflecting ARDS and sepsis progression respectively, were identified in H5N6 patients.
BibTeX
@misc{guan2023baloxavir,
  author = {Wenda Guan and Rong Qu and Lihan Shen and Kailin Mai and Weiqi Pan and Zhengshi Lin and Liping Chen and Ji Dong and Jiawei Zhang and Pei Feng and Yunceng Weng and Minfei Yu and Peikun Guan and Jinchao Zhou and Chuanmeizi Tu and Xiao Y. Wu and Yang Wang and Chunguang Yang and Yun Ling and Sheng Le and Yangqing Zhan and Yimin Li and Xiaoqing Liu and Heyan Zou and Ziqi Huang and Hongxia Zhou and Qiubao Wu and Wenjie Zhang and Jiayang He and Teng Xu and Nanshan Zhong and Zifeng Yang},
  title = {{Baloxavir marboxil use for critical human infection of avian influenza A H5N6 virus}},
  year = {2023},
  doi = {10.1101/2023.09.03.23294799},
  howpublished = {medRxiv},
}
Figure